Lexicon Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1995-01-01
- Employees
- 285
- Market Cap
- $621.7M
- Website
- http://www.lexpharma.com
- Introduction
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company...
Oral Contraceptive DDI Study
- Conditions
- Interventions
- First Posted Date
- 2015-07-10
- Last Posted Date
- 2016-03-02
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 30
- Registration Number
- NCT02494609
- Locations
- 🇺🇸
Lexicon Investigational Site, Dallas, Texas, United States
PK Study of Sotagliflozin in Subjects With Hepatic Impairment
- First Posted Date
- 2015-06-15
- Last Posted Date
- 2016-11-17
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 32
- Registration Number
- NCT02471274
- Locations
- 🇺🇸
Lexicon Investigational Site, Minneapolis, Minnesota, United States
Dose-ranging Study in Patients With Type 1 Diabetes Mellitus
- First Posted Date
- 2015-06-02
- Last Posted Date
- 2020-02-12
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 141
- Registration Number
- NCT02459899
- Locations
- 🇺🇸
Lexicon Investigational Site, Manassas, Virginia, United States
Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy
- First Posted Date
- 2015-04-20
- Last Posted Date
- 2020-02-12
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 782
- Registration Number
- NCT02421510
- Locations
- 🇬🇧
Lexicon Investigational Site, Sheffield, United Kingdom
Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy
- First Posted Date
- 2015-03-10
- Last Posted Date
- 2020-02-12
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 793
- Registration Number
- NCT02384941
- Locations
- 🇨🇦
Lexicon Investigational Site, St. Laurent, Quebec, Canada
Efficacy and Safety of Sotagliflozin in Young Adult Patients With Type 1 Diabetes Mellitus and Elevated Hemoglobin A1C
- First Posted Date
- 2015-03-10
- Last Posted Date
- 2020-02-12
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 87
- Registration Number
- NCT02383940
- Locations
- 🇺🇸
Lexicon Investigational Site, Salt Lake City, Utah, United States
Bioequivalence Study Between 400 mg LX4211 Tablets and 2 X 200 mg LX4211 Tablets
- First Posted Date
- 2015-02-26
- Last Posted Date
- 2015-10-02
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 30
- Registration Number
- NCT02373046
- Locations
- 🇺🇸
Lexicon Investigational Site, Dallas, Texas, United States
DDI Study With Multiple-dose LX4211 and Single Dose Digoxin
- Conditions
- Interventions
- First Posted Date
- 2014-11-25
- Last Posted Date
- 2015-07-09
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT02300350
- Locations
- 🇺🇸
Lexicon Investigational Site, Dallas, Texas, United States
DDI Study With Multiple-dose LX4211 and Single Dose Rosuvastatin
- Conditions
- Interventions
- First Posted Date
- 2014-11-25
- Last Posted Date
- 2015-07-09
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT02300363
- Locations
- 🇺🇸
Lexicon Investigational Site, Evansville, Indiana, United States
Phase 1, Open-label, Drug-drug Interaction Study With Octreotide Acetate Injection and Telotristat Etiprate in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-07-21
- Last Posted Date
- 2016-09-07
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT02195635
- Locations
- 🇺🇸
Lexicon Investigational Site, Daytona Beach, Florida, United States